The first reaction of ceramide glycosylation in sphingolipid metabolism is catalyzed by glucosylceramide synthase (GCS), which changes ceramide into glucosylceramide. By regulating ceramide and glycosphingolipids (GSLs), this glycosylation by GCS is a crucial step in controlling the modulation of cellular activities.Ceramide levels rise in response to stresses like chemotherapy, which causes cells to enter apoptosis or autophagy. Ceramide glycosylation, however, quickly removes ceramide and, as a result, these induced processes, protecting cancer cells. Additionally, persistently increased ceramide glycosylation can raise GSLs and contribute to the selection of drug-resistant cancer cells. In numerous drug-resistant cancer cells as well as breast, colon, and leukemia tumors that exhibit a poor response to chemotherapy, GCS is overexpressed. Inhibition of GCS makes cancer cells more susceptible to anticancer medications and kills cancer stem cells because ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V70294 | D-threo-PDMP | 109836-82-0 | D-threo-PDMP is a potent inhibitor of glucosylceramide synthase (GCS), which can reduce cell surface glycosphingolipids by inhibiting glycosylation, reducing the total length of axonal plexuses and the number of axonal branch points. |
|
V70297 | D-threo-PPMP | 139889-53-5 | D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. |
|
V70295 | D-threo-PPMP hydrochloride | 139889-65-9 | D-threo-PPMP HCl is a potent inhibitor of glucosylceramide (GlcCer) synthase. |
|
V79532 | Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) | Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyltransferase that catalyzes the transfer of focused residues from GDP-fucose to the innermost N-acetylglucosamine residues of N-glycans. | |
|
V3367 | Ibiglustat | 1401090-53-6 | Ibiglustat (formerly Venglustat; SAR-402671; GZ-402671; GZ-452; Genz-682452) is a novel, brain-penetrant, potent and selective allosteric Glucosylceramide synthase (GCS) inhibitor and ceramide glucosyltransferase inhibitor. |
|
V32453 | Ibiglustat L-Malic acid | 1629063-78-0 | Ibiglustat L-Malic acid(Venglustat; GZ402671;Genz-682452;GZ-452; SAR-402671)is a novel and potent inhibitor of glucosylceramide synthase (GCS) and also aceramide glucosyltransferase inhibitor. |
|
V70296 | Ibiglustat succinate (Venglustat succinate; SAR402671 succinate; GZ402671 succinate) | 1629063-80-4 | Ibiglustat (Venglustat) succinate is an orally bioactive, BBB (blood-brain barrier) permeable (penetrable) glucosylceramide synthase (GCS) inhibitor. |
|
V25528 | Miglustat HCl (OGT-918; NB-DNJ; Zavesca) | 210110-90-0 | Miglustat HCl (OGT-918;NB-DNJ;Zavesca)is an FDA approved drug used to treatType I Gaucher disease (GD1). |
|
V70293 | Nizubaglustat | 1633666-49-5 | Nizubaglustat is an inhibitor (blocker/antagonist) of ceramide glucosyltransferase or glucosylceramide synthase (GCS). |
|
V81662 | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II) | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II) is a glycosyltransferase. | |
|
V81797 | α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) | α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) is a glycosyltransferase. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
